Merck stock holds near recent highs as Keytruda and vaccine revenue support guidance

Merck & Co. stock (ISIN US58933Y1055) remains underpinned by robust earnings momentum, with recent quarterly figures showing double digit growth in core oncology and vaccine franchises that continue to anchor the companys outlook for 2025 and beyond.

Keytruda revenue up over 10 percent

According to Merck & Co.s latest available annual report for fiscal 2024, the company generated global revenue of around $63 billion in 2024, up roughly 6 percent from the prior year on a reported basis as strong oncology and vaccine demand offset biosimilars and foreign exchange headwinds.

Within that total, flagship cancer drug Keytruda contributed more than $25 billion in revenue in 2024, an increase of well over 10 percent compared with its prior year sales as the immunotherapy continued to gain share across multiple indications including lung cancer, melanoma and certain gastrointestinal tumors.

This double digit expansion in Keytruda revenue now accounts for roughly 40 percent of Merck & Co.s pharmaceutical sales, underscoring how the drug remains central to the companys margin and cash flow profile even as management invests heavily in next generation oncology assets.

Vaccine business reports solid growth

Merck & Co.s vaccine segment also delivered solid expansion in the latest reported period, with annual vaccine revenue rising to around $11 billion in 2024 versus approximately $10 billion in 2023, reflecting about 10 percent growth driven by higher demand for pediatric and adolescent vaccines as well as continued uptake of its human papillomavirus (HPV) vaccine franchise.

The HPV vaccine Gardasil, a core product in Merck & Co.s portfolio, is estimated to have contributed more than $7 billion in revenue in 2024, up from roughly $6 billion a year earlier, implying growth in the mid teens and highlighting the ongoing global public health focus on preventing HPV related cancers.

Margin performance in the vaccine segment benefited from the scale effects of growing volumes, with vaccine gross margin estimated to have improved by around 1 percentage point year on year in 2024, supporting Merck & Co.s overall operating margin despite rising research and development spending on new infectious disease candidates.

Guidance supported by pipeline investments

Management has indicated that research and development expenses reached roughly $14 billion in 2024, up from about $13 billion in 2023, an increase of roughly 8 percent as Merck & Co. expanded its late stage pipeline in oncology, cardiometabolic disease and vaccines.

These investments feed into the companys medium term guidance, which points to low to mid single digit annual revenue growth through 2025 on a reported basis, with higher potential growth on an ex foreign exchange basis if key pipeline assets such as novel oncology combinations and next generation vaccines successfully reach the market.

Keytruda remains a crucial bridge in this guidance framework because patent expiries are expected later in the decade, and Merck & Co.s strategy centers on extending the drug into earlier stages of disease and additional tumor types while advancing successor immunotherapies and targeted agents.

The company also continues to highlight its cardiovascular franchise as a secondary growth pillar, with investigational therapies in heart failure and hypercholesterolemia aiming to diversify earnings beyond oncology and vaccines and to mitigate concentration risk as Keytruda eventually faces competition.

Dividend and cash flow provide stability

Merck & Co. reported operating cash flow of roughly $20 billion in 2024, which together with a strong balance sheet supports ongoing dividend payments and potential selective bolt on acquisitions in areas such as oncology, infectious disease and immunology.

The annual dividend for 2024 amounted to around $3 per share, representing a modest increase compared with 2023 and implying a yield in the low single digits relative to Merck & Co.s typical trading range in recent months.

Net income for 2024 was reported at approximately $17 billion, up from roughly $14 billion in 2023, a rise of more than 20 percent that was driven primarily by the expanding contribution from Keytruda and vaccines alongside disciplined cost control in selling, general and administrative expenses.

For investors, the combination of growing cash flow, a consistent dividend and pipeline backed guidance provides a measure of stability even as the company navigates the long term challenge of replacing Keytrudas eventual revenue stream.

Keytruda anchors oncology strategy

Keytruda remains Merck & Co.s most important product, and its role in the oncology strategy is central to the companys earnings profile and capital allocation decisions, reflected in the more than $25 billion of 2024 revenue and its double digit growth versus 2023.

The drug is approved for a broad range of cancers, including non small cell lung cancer, melanoma, head and neck cancer and several gastrointestinal tumors, and ongoing studies aim to move Keytruda into early stage disease settings where longer treatment durations could further enhance its revenue potential.

Merck & Co. is also pursuing combination regimens that pair Keytruda with chemotherapy, targeted agents or other immunotherapies, seeking incremental improvements in response rates and survival that can solidify the drugs position against competing checkpoint inhibitors and emerging oncology modalities.

Beyond Keytruda, the companys oncology pipeline includes multiple investigational agents in immuno oncology and precision oncology, which are intended to gradually broaden the therapeutic base and reduce dependency on a single product as the patent clock advances.

Merck stock supported by earnings and pipeline

Merck & Co. stock trades on the New York Stock Exchange and has in recent months oscillated around a price level that reflects its position as a large, diversified pharmaceutical group within the S&P 500 index, with valuation anchored by the strong earnings growth reported in 2024 and the visibility of Keytruda and vaccine cash flows.

Market capitalization stands in the range of $300 billion as of mid 2025, reflecting the scale of Merck & Co.s global operations and the markets expectation that double digit revenue growth from oncology and vaccines can continue to support overall group expansion in the near term.

Relative to peers in the global pharmaceutical sector, Merck & Co.s growth profile, cash flow generation and dividend discipline contribute to a perception of resilience, while the high concentration in a single blockbuster drug remains a strategic consideration that investors monitor through pipeline milestones and business development activity.

Keytruda drives Merck & Co. portfolio

Keytruda is the core product in Merck & Co.s oncology portfolio and has become one of the worlds top selling medicines, with more than $25 billion in 2024 revenue and growth of over 10 percent year on year.

The drugs clinical data set covers numerous cancer types, and ongoing trials in earlier disease stages and new combinations aim to strengthen its competitive position and extend its lifecycle, even as biosimilar development and novel oncology mechanisms progress in the broader industry.

Merck & Co.s commercial strategy for Keytruda includes expanding access in emerging markets, optimizing pricing and reimbursement in established markets and leveraging real world evidence to support clinical decisions, all of which contribute to the drugs revenue trajectory and strategic importance.

Merck stock closes with large cap resilience

Merck & Co. stock currently reflects its status as a large cap pharmaceutical name on the New York Stock Exchange, with a market capitalization around $300 billion as of mid 2025 and valuation supported by the more than $25 billion Keytruda revenue, roughly $11 billion vaccine sales and approximately $63 billion total revenue recorded in 2024.